Video

Use of aflibercept in the management of diabetic retinopathy

Author(s):

David Hutton,Emily Kaiser Maharjan
Conferences|ASRS Preview

Lloyd Clark, MD, highlights his ASRS presentation focusing on the PANORAMA study detailing the use of aflibercept in the management of diabetic retinopathy.

Lloyd Clark, MD, of Palmetto Retina Center, previews his ASRS poster, which focuses on the PANORAMA Study, which reviews the use of aflibercept in the management of diabetic retinopathy. He will present his poster during a reception on July 15 at this year’s American Society of Retina Specialists meeting in New York.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
Related Content
Q&A: Siegfried Priglinger, MD, on the long-term outcomes of gene therapy in preschool kids
June 9th 2025

Q&A: Siegfried Priglinger, MD, on the long-term outcomes of gene therapy in preschool kids

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Q&A: Jay Chhablani, MD, discusses 3D choroidal vasculature analysis
June 8th 2025

Q&A: Jay Chhablani, MD, discusses 3D choroidal vasculature analysis

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

(Image credit: AdobeStock/zinkevych) FDA nod for acoltremon: What its approval means for clinicians and patients
June 7th 2025

FDA nod for acoltremon: What its approval means for clinicians and patients

Q&A: The ELEVATUM Study with J. Fernando Arevalo
June 7th 2025

Q&A: The ELEVATUM Study with J. Fernando Arevalo

© 2025 MJH Life Sciences

All rights reserved.